FRIDAY, DECEMBER 13 BREAKOUT SESSION

---

Genomic Landscape of Prostate Cancer and Implications for Therapy selection

Gennady Bratslavsky, MD

Role of Theranostics and PARP Inhibitors

Cora Sternberg, MD, FACP

Updates in Neoadjuvant Therapy Trials for Prostate Cancer

Brian Chapin, MD

New Treatments for Advanced Prostate Cancer

William Oh, MD

Treatment De-Escalation in Metastatic Hormone-Sensitive PCa

Che-Kai Tsao, MD, MS

Transaltional Analyses from STAMPEDE inc Expression Profiling (presented ESMO24) and Also Long Term Risk of Fractures (ESMO 23 and EAU 23) 

Nick James, MBBS, PhD

Advanced Staged Pca (Research)

Christina Jamieson, MD

Q&A

Pushing the Limits of Focal Therapy: How Much Pattern 4 is Acceptable?

Art Rastinehad, DO

Why Cryotherapy is My Preferred Modality for Prostate Ablation

Michael Gorin

Q&A

Break / Visit Exhibits / Visit Abstract Session

RaPiDS in Kidney Cancer: Advancements in Drug Sensitivity Assessment and Future Directions

Ben Hopkins, PhD

Exploitation of Metabolic Pathways for Therapeutic Targeting of Advanced Renal Cancer

Roberto Pili, MD

Molecular Mechanisms Driving Renal Cancer Progression and Therapeutic Resistance with Focus on the Role of Molecular Chaperone Hsp90

Mehdi Mollapour, PhD

Advances in Kidney Cancer: Quantitative Ultrasound Innovations and Applications

Jonathan Mamou, MD

Q&A

Return to Main Session